(Total Views: 550)
Posted On: 03/22/2021 5:10:31 PM
Post# of 145248
![Avatar](https://investorshangout.com/images/ProfileImages/1227900469_64555_mark.jpg)
CD16 was good to go, but they decided to get more specific and split into:
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
CD16 for patients <65, endpoint alive with no respiratory failure
CD17 >= 65, Intravenous initial dose, followed by two subcutaneous
both of these should dispel any doubt about results, delay's worth it imo
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)